TORONTO, June 29, 2022 (GLOBE NEWSWIRE) — Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic-inspired medicines to treat neurological and psychiatric disorders with unmet medical needs, today announced that the Company has developed a novel…


Previous articleOptimi Health Initiates Agreement With SABI Mind For Therapeutic Supplies Of Psilocybin, MDMA
Next articleTryp Therapeutics Strengthens IP Portfolio with Provisional Patent Application for Binge Eating Disorder Treatment